Business
Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6
Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6\n\n\n\n\n\nRegen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6\nCompany Gets a Lead on Developing Small Molecule Immune Suppressants\nPR Newswire\nSAN DIEGO, June 14, 2016\n\n\n\nSAN DIEGO, June 14, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today identification of small molecules that activate the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.  Previously, the Company reported that suppressing NR2F6 leads to immune cell activation, including production of the immune-stimulatory cytokines IL-18, IL-17 and IL-2.  Thus, activating NR2F6 will likely lead to immune suppression.\n\n\"As previously stated, we are currently screening several well thought out chemical libraries designed to give us new chemical entities which inhibit and/or activate NR2F6. We are optimistic that this program will identify lead compounds in the next several months and create a new generation of both immune-stimulatory anticancer drugs and immune-inhibitory drugs. The discovery of some molecules that bind to and activate NR2F6 opens significant possibilities in developing an oral drug that suppresses the immune system and can be used to fight autoimmune disorders such as lupus, graft versus host disease, eczema and rheumatoid arthritis,\" said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.\n\nGiven the difficult nature of the NR2F6 target, Regen is excited that using very stringent parameters, the Company has been able to identify molecules that not only bind and activate it but also have structural properties making them excellent starting points for drug development.  Regen is also optimistic the Company will identify inhibitors of NR2F6 in the coming months.\"\n\nNR2F6 is a molecular switch known as a \"orphan nuclear receptor\" which controls genes associated with the immune response.  Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology.  Issued US Patent # 9091696 was assigned ...